January 16, 2018 / 12:39 PM / a month ago

BRIEF-Merck & Co Says Keytruda Phase 3 Keynote-189 Trial Met Its Dual Primary Endpoints

Jan 16 (Reuters) - Merck & Co Inc:

* MERCK‘S KEYTRUDA(R) (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AS FIRST-LINE TREATMENT IN COMBINATION WITH PEMETREXED AND PLATINUM CHEMOTHERAPY FOR PATIENTS WITH METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (KEYNOTE-189)

* MERCK & CO INC - PIVOTAL PHASE 3 KEYNOTE-189 TRIAL MET ITS DUAL PRIMARY ENDPOINTS

* MERCK & CO INC - ‍SAFETY PROFILE OF KEYTRUDA IN COMBINATION WAS CONSISTENT WITH THAT PREVIOUSLY OBSERVED​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below